Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen

To assess the efficacy and safety of dual-antiretroviral therapy containing a ritonavir-boosted protease inhibitor (PI/r) in treatment-experienced patients failing a current antiretroviral regimen. Retrospective analysis of 60 consecutive HIV-1-infected patients who started a dual-antiretroviral res...

Descripción completa

Detalles Bibliográficos
Autores: Burgos, J, Crespo, M, Falco, V, Curran, A, Imaz, A, Domingo, P, Podzamczer, D, Mateo, MG, Van den Eynde, E, Villar, S, Ribera, E
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2012
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p11341
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=11341
Access Level:acceso abierto
Palabra clave:dual-antiretroviral therapy
salvage therapy
pre-treated HIV-infected patients
id ES_a4134ff4e77446e1db4fc224e1243b05
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p11341
network_acronym_str ES
network_name_str España
repository_id_str
spelling Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimenBurgos, JCrespo, MFalco, VCurran, AImaz, ADomingo, PPodzamczer, DMateo, MGVan den Eynde, EVillar, SRibera, Edual-antiretroviral therapysalvage therapypre-treated HIV-infected patientsTo assess the efficacy and safety of dual-antiretroviral therapy containing a ritonavir-boosted protease inhibitor (PI/r) in treatment-experienced patients failing a current antiretroviral regimen. Retrospective analysis of 60 consecutive HIV-1-infected patients who started a dual-antiretroviral rescue regimen containing a PI/r, in three hospitals in Spain. Virological failure was defined as confirmed HIV RNA 50 copies/mL at treatment week 24 or later. The percentage of patients remaining free of therapeutic failure was estimated using the KaplanMeier method, by intent-to-treat analysis (missing, changes and virological failuretherapeutic failure). Median baseline characteristics of patients were: 13 years on antiretroviral therapy (four prior highly active antiretroviral therapy regimens and eight different drugs), 380 CD4 cells/mm(3) and HIV RNA 3.04 log(10) copies/mL. All patients had resistance mutations to at least two drug classes, although only 9.3 had specific mutations to darunavir. A darunavir-based regimen was started in 47 (78.4) patients, combined with etravirine (26.7), tenofovir (26.7) or raltegravir (25). Three (5) patients discontinued treatment due to side effects. At the end of follow-up, 86.7 of patients remained free of therapeutic failure; the percentages of patients with no therapeutic failure at treatment weeks 24, 48 and 96 were 96.6 (95 CI, 91.9101.3); 90.1 (95 CI, 81.998.3) and 79.8 (95 CI, 66.193.5), respectively. Our results suggest that a dual-therapy rescue regimen including a PI/r is convenient, well tolerated and potent enough to achieve persistent viral suppression in selected pre-treated patients with low viral load and few PI resistance mutations.OXFORD UNIV PRESS2012info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=11341JOURNAL OF ANTIMICROBIAL CHEMOTHERAPYISSN: 03057453ISSNe: 14602091reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p113412026-06-14T12:41:47Z
dc.title.none.fl_str_mv Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen
title Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen
spellingShingle Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen
Burgos, J
dual-antiretroviral therapy
salvage therapy
pre-treated HIV-infected patients
title_short Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen
title_full Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen
title_fullStr Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen
title_full_unstemmed Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen
title_sort Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen
dc.creator.none.fl_str_mv Burgos, J
Crespo, M
Falco, V
Curran, A
Imaz, A
Domingo, P
Podzamczer, D
Mateo, MG
Van den Eynde, E
Villar, S
Ribera, E
author Burgos, J
author_facet Burgos, J
Crespo, M
Falco, V
Curran, A
Imaz, A
Domingo, P
Podzamczer, D
Mateo, MG
Van den Eynde, E
Villar, S
Ribera, E
author_role author
author2 Crespo, M
Falco, V
Curran, A
Imaz, A
Domingo, P
Podzamczer, D
Mateo, MG
Van den Eynde, E
Villar, S
Ribera, E
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv dual-antiretroviral therapy
salvage therapy
pre-treated HIV-infected patients
topic dual-antiretroviral therapy
salvage therapy
pre-treated HIV-infected patients
description To assess the efficacy and safety of dual-antiretroviral therapy containing a ritonavir-boosted protease inhibitor (PI/r) in treatment-experienced patients failing a current antiretroviral regimen. Retrospective analysis of 60 consecutive HIV-1-infected patients who started a dual-antiretroviral rescue regimen containing a PI/r, in three hospitals in Spain. Virological failure was defined as confirmed HIV RNA 50 copies/mL at treatment week 24 or later. The percentage of patients remaining free of therapeutic failure was estimated using the KaplanMeier method, by intent-to-treat analysis (missing, changes and virological failuretherapeutic failure). Median baseline characteristics of patients were: 13 years on antiretroviral therapy (four prior highly active antiretroviral therapy regimens and eight different drugs), 380 CD4 cells/mm(3) and HIV RNA 3.04 log(10) copies/mL. All patients had resistance mutations to at least two drug classes, although only 9.3 had specific mutations to darunavir. A darunavir-based regimen was started in 47 (78.4) patients, combined with etravirine (26.7), tenofovir (26.7) or raltegravir (25). Three (5) patients discontinued treatment due to side effects. At the end of follow-up, 86.7 of patients remained free of therapeutic failure; the percentages of patients with no therapeutic failure at treatment weeks 24, 48 and 96 were 96.6 (95 CI, 91.9101.3); 90.1 (95 CI, 81.998.3) and 79.8 (95 CI, 66.193.5), respectively. Our results suggest that a dual-therapy rescue regimen including a PI/r is convenient, well tolerated and potent enough to achieve persistent viral suppression in selected pre-treated patients with low viral load and few PI resistance mutations.
publishDate 2012
dc.date.none.fl_str_mv 2012
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=11341
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=11341
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv OXFORD UNIV PRESS
publisher.none.fl_str_mv OXFORD UNIV PRESS
dc.source.none.fl_str_mv JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
ISSN: 03057453
ISSNe: 14602091
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415449936003072
score 15.812455

Similares en LA Referencia